PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q80589

Masahiro OKUDA, et al.

Appln. No.: 10/811,385

Group Art Unit: 1644

Confirmation No.: 3080

Examiner: Yunsoo KIM

Filed: March 29, 2004

For: REAGENT FOI

REAGENT FOR DETECTING ANTI-PHOSPHOLIPID ANTIBODY AND REAGENT

KIT USING THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore Applicant is submitting concurrently herewith the required fee under 37 C.F.R. § 1.17(p).

Atty, Docket No. O80589

INFORMATION DISCLOSURE STATEMENT Appln. No. 10/811,385

The required copies of the listed documents have been provided in co-pending Application Nos. 10/662,736 or 11/050,766, and therefore are not being re-submitted. The listed documents were cited as references of record in co-pending U.S. Application Nos. 10/622,736 and 11/050,766; references that were cited in U.S. Application Nos. 10/622,736 or 11/050,766, but which have already been cited in the present application, are not re-listed herein.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: June 18, 2007

Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Comp	olete if Known	
Application Number	10/811,385	
Confirmation Number	3080	
Filing Date	March 29, 2004	
First Named Inventor	Masahiro OKUDA	
Art Unit	1644	
Examiner Name	Yunsoo KIM	
Attorney Docket Number	Q80589	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document No		Publication Date			
	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Docume		
		US 5,453,370	1	09-26-1995	Triplett et al.		
		US 5,314,695	1	05-24-1994	Brown, Scott M.		
			05-28-2002	Rosen et al.			
			01-06-1998	Triplett et al.			
		US 6,777,193		08-17-2004	Bacza-Ramirez et al.		
		US 2003/0232075		12-18-2003	Nelsestuen, Gary L.		
		US 2004/0091952		05-13-2004	Okuda		
		US 2004/0197837	1	10-07-2004	Okuda et al.		
		US 2007/0026467		02-01-2007	Greenfield et al.		

FOREIGN PATENT DOCUMENTS							
Examiner Cite	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	
Initiais*	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		JP	2004109034		04-08-2004	Kato et al.	
***		EP	0 566 333	A1	10-20-1993	ORTHO DIAGNOSTIC SYSEMS INC	
		EP	1 385 003	Al	01-28-2004	SYSMEX CORP	
		 					
		-					
		—					
1							
							İ

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.						
		P.R. Kelsey, et al. "The diagnosis of Lupus Anticoagulants by the Activated Partial Thromboplastin Time- The Central Role of Phosphatidyl Serine" Thrombosis and Haemostasis 1984 Germany, Vol. 52, No. 2, 1984, pages 172-175 XP008042549						
		Slater, P. J., et al. "Pro Coagulant Activity of Partial Thromboplastin Cephalin Reagent and Its Phosphor Lipid Composition" Thrombosis Research, Vol. 18, No. 6, 1980, pages 831-838, XP008024695 ISSN: 0049-3848						
		S. KITCHEN et al, Lipid Composition Of Seven APTT Reagents In Relation To Heparin Sensitivity, British Journal of Haematology, 1999, p801-808, vol. 106						
		Smirnov et al. "The effect of membrane composition on the hemostatic balance" Biochemistry (1999) 38: 3591-3598.						
		Webster's II New Riverside University Dictionary (1994) (Houghton Mifflin Co.: Boston, MA) p.667.						

Examiner Signature		Date Considered		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP of	509. Draw	line through citation if not	in conformance and not considered.	Include copy of
this form with next communication to applicant.				

Applicant's unique testion designation number (optional). "See Kind Codes of USPTO Passo Documents at wave supple, gar, APED 90). Mor of Globs or beying the from the till of the Comments to the interest." Destroy Office that interest the Codes of the Passon Documents to the interest. "For Office that interest the Codes of the Passon Documents that is a finished and comments." "Asked of Government by the appropriate symbols as indicated on the choice under WIPO Standard ST, 16 if possible." Applicant is to indicate their Eligible Insurger Treatments in structure.

ubstitute for Form 1449 A & B/PTO				Complete if Known		
ubstitute for Form 144	itute for Form 1449 A & B/PTO		Application Number	10/811,385		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			STODE	Confirmation Number	3080	
				Filing Date	March 29, 2004	
			ANI	First Named Inventor	Masahiro OKUDA	
			ury)	Art Unit	1644	
	•		•	Examiner Name	Yunsoo KIM	
Sheet	2	of	2	Attorney Docket Number	Q80589	

U.S. PATENT DOCUMENTS								
	Cite	Document	Number	Publication Date				
	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
		US						
		US						
		US						
		US						
		US						
		US						
		ÚS						
		US						
		US						

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Cite Foreign Patent Document		Publication Date	Name of Patentee or			
Initials*	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation	
								
				+				
				 				
				7				

		NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dute, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation
		SCHJETLEIN, R. et al., "A Quantitative, Semi-Automated and Computer-Assisted Test for Lupus	
		Anticoagulant," Thrombosis Research 69, 1993, pages 239-250	
		Astumi et al. (abstract) Igaku to Yakugaku, vol. 45(1), 2001, pages 123-127.	
			l

Examiner Signature	Date Considered	
Danister or Reserve		

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is suggestation, designation marker (optional). "See Kind Codes of USPTO Detail Decomments as waverapte, gap, MEDP 90). Not of Glow by hoperisk from the filte of the Comment to the interval. - Elect office that it issued the Comment, by the investment to the Investment of the Comment, by the investment to the Investment of the Investment of the Investment of the Investment precede the section annihing of the Empower mental precede the section annihing of the Empower mental precede the section annihing of the Investment